

1 **Exploring the Trajectory of Catatonia in Neurodiverse and Neurotypical Pediatric**

2 **Hospitalizations: A Multicenter Longitudinal Analysis**

3 Running title: Hospitalizations for Pediatric Catatonia

4 James Luccarelli, MD, DPhil<sup>1,2</sup>

5 Jacqueline A. Clauss, MD, PhD<sup>1,2</sup>

6 Tasia York, MD<sup>3</sup>

7 Isaac Baldwin, MD<sup>4</sup>

8 Simon Vandekar, PhD<sup>5</sup>

9 Trey McGonigle, MS<sup>5</sup>

10 Gregory Fricchione, MD<sup>1,2</sup>

11 Catherine Fuchs, MD<sup>3</sup>

12 Joshua R. Smith, MD<sup>3,6</sup>

13

14 Author Affiliations:

15 <sup>1</sup>Harvard Medical School, Boston, MA, USA

16 <sup>2</sup>Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA

17 <sup>3</sup>Division of Child and Adolescent Psychiatry, Department of Psychiatry and Behavioral  
18 Sciences, Vanderbilt University Medical Center, Nashville, TN

19 <sup>4</sup>Division of General Psychiatry, Department of Psychiatry and Behavioral Sciences; Vanderbilt  
20 University Medical Center, Nashville, TN

21 <sup>5</sup>Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN

22 <sup>6</sup>Vanderbilt Kennedy Center, Vanderbilt University, Nashville, TN, 37203

23

24 Corresponding Author: James Luccarelli, MD, DPhil

25 Address: Massachusetts General Hospital, 32 Fruit Street, Yawkey 6A, Boston MA 02114

26 Email: [jluccarelli@mgb.org](mailto:jluccarelli@mgb.org)

27 Phone: 617-726-2000

28 Fax: 606-206-8090

29

30 **Conflicts of Interest**

31 JL receives funding from Harvard Medical School Dupont Warren Fellowship and Livingston  
32 Awards, the Rappaport Foundation, and the Foundation for Prader-Willi Research. He has  
33 received equity and consulting fees from Revival Therapeutics, Inc. JAC receives funding from  
34 the Harvard Medical School Dupont-Warren Fellowship, the Chen Institute Mass General  
35 Neuroscience Transformative Scholar Award, and the Louis V. Gerstner Award. GF has received  
36 equity from Revival Therapeutics, IP royalties from Adya Health and is on the scientific  
37 advisory board of Being Health. JRS receives funding from Roche, Axial Therapeutics, and the  
38 National Institute of Child and Human Development. All other authors report no disclosures.

39

40 **Funding:**

41 This work was supported by the National Institute of Mental Health (T32MH112485; JL and  
42 JAC) and National Institute of Child and Human Development (1P50HD103537; JRS). The  
43 sponsor had no role in study design, writing of the report, or data collection, analysis, or  
44 interpretation.

45

46 **Keywords:**

47 catatonia, cohort studies, child psychiatry, neurodevelopmental disorders

48

49 Word Count: 2790

50 # of Tables and Figures: 4

51 **Abstract**

52 Objective: Catatonia is a neuropsychiatric disorder that occurs in pediatric patients with a range  
53 of associated medical, psychiatric, and neurodevelopmental disorders (NDDs). This study  
54 describes hospital care of pediatric catatonia patients and compares treatments for neurotypical  
55 patients and those with NDDs.

56 Methods: Retrospective cohort study from 1/1/2018 to 6/1/2023 of two academic medical centers  
57 of patients aged 18 and younger with catatonia. Patients were retrospectively assessed using the  
58 clinical global impressions-improvement (CGI-I) by two independent reviewers.

59 Results: One hundred sixty-five patients were hospitalized for catatonia, of whom 50.3% had an  
60 NDD. Median age was 15. One hundred sixty-four patients were treated with a benzodiazepine,  
61 with a median maximum 24-hour dose of 6 mg lorazepam-equivalents, which did not differ for  
62 patients with and without NDDs. Electroconvulsive therapy (ECT) was utilized in 14.5% of  
63 patients. Median length of medical hospitalization was 5 days and hospitalizations were longer in  
64 neurotypical patients than in patients with NDDs. In an ordinal regression model, the probability  
65 of observing at least “much improvement” (CGI < 3) was 88.3% (95% CI: 82.4% to 92.3%),  
66 with NDD diagnosis associated with a lower odds of clinical response.

67 Conclusions: The probability of patients achieving a CGI-I score indicating at least “much  
68 improvement” was 88.3%. Administered benzodiazepine dose and ECT treatment were similar  
69 for all patients, but neurotypical patients had longer hospitalizations than those with NDDs and  
70 had a higher odds of a more favorable clinical response. Research under controlled conditions is  
71 needed to optimize and endure equitable catatonia treatment in youth.

## 72 **Introduction**

73           Catatonia is a neuropsychiatric disorder which occurs across the lifecycle and is  
74 characterized by psychomotor disturbance, affective dysregulation, unique physical examination  
75 findings, and possible autonomic dysfunction.<sup>1-4</sup> Symptoms may fluctuate rapidly during periods  
76 of illness, for instance at times presenting with muteness and stupor and at other times presenting  
77 with repetitive speech and ceaseless motion. Catatonic symptoms can be severe in nature,  
78 warranting inpatient medical care due to dehydration, poor intake of food and water, intractable  
79 aggression and hyperactivity, and autonomic instability. Children with catatonia are at a  
80 significantly elevated risk for morbidity and a 63-fold increased rate of mortality compared to  
81 same-age peers.<sup>5</sup> If correctly identified, however, pediatric catatonia often responds rapidly to  
82 treatment.<sup>6,7</sup> Thus, the identification and treatment of pediatric catatonia in the inpatient pediatric  
83 medical setting presents a unique opportunity for prompt and significant intervention which may  
84 drastically improve a child's course of illness.<sup>8-10</sup>

85           Along with medically ill children, neurotypical children with psychiatric disorders and  
86 neurodiverse children are at significantly elevated risk of catatonia.<sup>7,11-13</sup> For neurodiverse  
87 individuals, catatonia often presents as a deviation in baseline functioning.<sup>14</sup> Common features of  
88 neurodevelopmental disorders (NDDs), including alterations of speech, eye contact, non-verbal  
89 communication, stereotypes, mannerisms, and motor function, may overlap at baseline with  
90 catatonic signs.<sup>15,16</sup> In addition, the traditionally utilized Bush Francis Catatonia Rating Scale  
91 (BFCRS) is validated for neurotypical adults, and the pediatric catatonia rating scale (PCRS) is  
92 validated for neurotypical children; these scales may miss symptoms present in neurodiverse  
93 individuals with catatonia, including recurrent self-injury and loss of previously acquired  
94 skills.<sup>17,18</sup> The accumulation of these challenges likely results in a delayed time to diagnosis and

95 treatment.<sup>19</sup> However, to date, we do not understand if neurodiverse children have a different  
96 longitudinal course of catatonic symptoms or if traditional first-line approaches, including  
97 benzodiazepines and electroconvulsive therapy, are equally efficacious between neurotypical and  
98 neurodiverse children.

99         Despite the morbidity associated with catatonic symptoms, catatonia remains  
100 understudied, especially in children. Currently, there are no comprehensive studies of the course  
101 of illness or typical treatment needed to manage catatonia in children. There also remains a  
102 significant gap in understanding how neurotypical children and children with NDD might differ  
103 in their illness course and treatment. The aim of this study is to characterize, to our knowledge,  
104 the largest sample to date of inpatient children hospitalized with pediatric catatonia. Specifically,  
105 we will examine the course, duration, and response to treatment of pediatric catatonia in the  
106 inpatient medical setting. We will then compare these outcomes between neurotypical and  
107 neurodiverse children.

## 108 **Methods**

### 109 **Data Source**

110         The clinical cohort was identified as previously described.<sup>4</sup> Clinical records from two  
111 large health systems were queried for patients between 1/1/2018 and 6/1/2023 aged 18 and  
112 younger and with a discharge diagnostic code for catatonia (F06.1 or F20.2). Identified records  
113 were then manually reviewed and patients included if they had a clinical diagnosis of catatonia,  
114 as confirmed in clinical documentation and full Bush Francis Catatonia Rating Scale (BFCRS)<sup>20</sup>  
115 documented at the time of initial catatonia diagnosis. This study was approved by the

116 Institutional Review Board of each study site (Vanderbilt University IRB: 230097; Mass General  
117 Brigham IRB: 2022P000811) with a waiver of informed consent from participants.

#### 118 Data Extraction

119 Age, sex, race, ethnicity, and clinical diagnoses were extracted from the electronic health  
120 record. Patients were defined as having a NDD if an ICD-10-CM diagnosis under the headings  
121 F70-79 “Intellectual disabilities” or F80-89 “Pervasive and specific developmental disorders”  
122 was present.<sup>21</sup> The principal reason for hospitalization was determined from the hospital  
123 discharge summary. The principal reason for hospitalization was categorized as unspecified  
124 catatonia, mood or trauma-spectrum disorders, psychotic disorders, medical diagnoses, or  
125 neurodevelopmental disorders. Length of medical hospitalization was also extracted from the  
126 discharge summary. In cases where the individual was transferred from an acute medical  
127 hospitalization to a psychiatric hospital or rehabilitation hospital and records were available for  
128 the psychiatric or rehabilitation hospitalization following transfer, the LOS for both periods were  
129 combined into an overall LOS. Initial BFCRS, discharge BFCRS (if present), maximum 24-hour  
130 benzodiazepine dosing (in milligrams of lorazepam equivalents, with 0.5 mg clonazepam, 5 mg  
131 of diazepam, and 2 mg of midazolam considered equivalent to 1 mg lorazepam), discharge  
132 benzodiazepine dosing (in milligrams of lorazepam equivalents), and the performance of  
133 electroconvulsive therapy (ECT) during hospitalization (yes/no) were extracted from the  
134 medication administration record and clinical notes.

135 A retrospective clinical global impressions-improvement (CGI-I)<sup>22</sup> score was assigned  
136 for each patient between time of admission and time of discharge. The CGI-I score was  
137 determined independently by two raters at each study site based on review of clinical  
138 documentation of each patient, including admission records, discharge records, progress notes,

139 and nursing notes. Each author was blinded to the results determined by their co-authors; thus  
140 two separate retrospective CGI-I scores were computed for each patient by four separate raters.

#### 141 Statistical Analysis

142 Demographics and diagnoses are presented using descriptive statistics, with patients with  
143 and without NDD diagnoses compared using  $\chi^2$  and Mann–Whitney U tests. Differences in  
144 BFCRS at time of diagnosis and at discharge were compared using paired t-tests. Interrater  
145 reliability appropriate for the ordinal retrospective CGI-I scores were calculated for each site  
146 using Gwet’s AC<sub>2</sub>.<sup>23</sup> Using CGI-I data, we fit an ordinal regression model adjusting for reviewer  
147 accounting for intra-subject correlation using robust standard errors with a working  
148 independence covariance structure.<sup>24,25</sup> An additional ordinal regression model was run with age,  
149 sex, study site, index BFCRS score, and NDD diagnosis (yes/no) as independent variables. All  
150 tests were 2-sided, with a prespecified significance threshold of  $p < 0.05$ , without correction for  
151 multiple testing. Statistical analyses were performed using SPSS (Version 29.0. Armonk, NY:  
152 IBM Corp) and R Statistical Software (v4.2.1; R Core Team 2022). Statistical output and code  
153 for the regression analyses are included in the Supplementary Material.

#### 154 Results

155 In total, 165 patients met inclusion criteria, including 92 males (55.8%) and 73 females  
156 (44.2%) (Table 1). Median age was 15 years, with an interquartile range of 12 to 16. NDDs were  
157 present for 83 patients (50.3%), which included autism spectrum disorder without intellectual  
158 impairment (N=30, 36.1%), autism spectrum disorder with intellectual disability (N=28, 33.7%),  
159 intellectual disability (N=8, 9.6%), and other neurodevelopmental disorders (N=17, 20.5%).  
160 Compared to neurotypical youth with catatonia, patients with NDDs and catatonia were younger

161 (median of 14 years vs. 15;  $U = 2504$ ,  $p = 0.003$ ), more likely to be male (63.9% vs. 47.6%;  
162  $\chi^2 (1, N = 165) = 4.44$ ,  $p = 0.035$ ), less likely to be Hispanic (8.4% vs. 22.0%;  $\chi^2 (1, N = 165) =$   
163  $5.86$ ,  $p = 0.015$ ), and had higher initial BFCRS scores (median of 17 vs. 14;  $U = 2744$ ,  $p =$   
164  $0.031$ ).

165 One-hundred sixty-four (164, 99.4%) patients were treated with a benzodiazepine during  
166 hospitalization, with 128 (78.5%) receiving treatment with one benzodiazepine medication  
167 (lorazepam in 112, clonazepam in 14, and diazepam in 2), 30 (18.4%) receiving two different  
168 benzodiazepines during hospitalization, and 6 (3.6%) receiving three or more benzodiazepines.  
169 The number of benzodiazepines received by neurotypical children and those with NDDs was  
170 significantly different ( $\chi^2 (2, N = 164) = 6.57$ ,  $p = 0.035$ ), with 86.4% of neurotypical children  
171 treated with a single benzodiazepine compared to 69.9% of children with NDDs. The median  
172 maximum benzodiazepine dose in a 24-hour period was 6 mg of lorazepam (IQR 3 to 12), which  
173 did not differ between patients with and without NDDs ( $U = 3202$ ,  $p = 0.691$ ) (Table 2). At time  
174 of discharge 147 patients (89.1%) remained on a benzodiazepine, with a median discharge dose  
175 of 3 mg of lorazepam in a 24-hour period (IQR 1.5 to 6). The median discharge dose did not  
176 differ between patients with and without NDDs ( $U = 3197$ ,  $p = 0.587$ ). The distribution of  
177 maximum and discharge benzodiazepine doses is graphed in Figure S1.

178 Discharge BFCRS was documented for 103 patients (62.4%). Among these individuals,  
179 BFCRS decreased significantly from  $16.3 \pm 6.2$  at baseline to  $4.7 \pm 4.4$  at discharge (mean  
180 difference: 11.7;  $t(102) = 17.4$ ;  $p < 0.001$ ). The distribution of index and discharge BFCRS for  
181 these patients is graphed in Figure 1 and Figure S2.



182           The median duration of medical hospitalization for all patients was 5 days, with an IQR  
183   of 3 to 13. Medical hospitalization exceeded 30 days for 9.8% of patients, with a maximum LOS  
184   of 118 days. Neurotypical children had a longer medical LOS (median of 8 days vs. 5 for those  
185   with NDD;  $U = 2604$ ,  $p = 0.017$ ). Following medical hospitalization, 63 individuals (38.2%) went  
186   on to further psychiatric hospitalization, including 51.2% of neurotypical children and 25.3% of  
187   neurodiverse children, a difference that was statistically significant ( $\chi^2(1, N = 165) = 11.7$ ,  $p <$   
188    $0.001$ ). Length of psychiatric hospitalization was available for 55 of these patients (87.3%) and  
189   was a median of 16 days, with an IQR of 10 to 31 days. Index BFCRS was not significantly  
190   associated with length of medical hospitalization (Pearson correlation = 0.009; 95% CI: -0.145 to  
191   0.162) or combined length of medical and psychiatric hospitalization (Pearson correlation = -  
192   0.023; 95% CI: -0.179 to 0.135). Index BFCRS vs. medical LOS is graphed in Figure 2, and  
193   index BFCRS vs. overall LOS in Figure S3. One-hundred and fifty (90.9%) patients were  
194   discharged home after medical or psychiatric hospitalization, which was not significantly  
195   different between those with and without NDDs. There was one in-hospital death in a patient  
196   with a pediatric cancer diagnosis.

197           Overall change in illness severity between admission and discharge was quantified  
198   retrospectively for each patient using the CGI-I scale, with two reviewers independently  
199   assessing the full text of each chart. Interrater reliability for CGI-I scores was assessed using  
200   Gwet's  $AC_2$  and was 0.80 (95% CI: 0.76 to 0.84) for Site 1 and 0.73 (95% CI: 0.53 to 0.94) for  
201   Site 2, indicating moderate to high correlation between reviewers. Using the CGI-I data, we fit  
202   an ordinal regression model adjusting for reviewer with robust standard errors to investigate the  
203   probability of observing improvement while accounting for intra-rater correlation. In this model,  
204   the probability of observing at least "minimal improvement" ( $CGI < 4$ ) was 98.5% (95% CI:

205 95.4% to 99.5%), while corresponding probability of at least “much improved” (CGI < 3) was  
206 88.3% (95% CI: 82.4% to 92.3%), and the probability of “very much improved” (CGI = 1) was  
207 23.0% (95% CI: 17.7% to 29.2%) (Table 3). In a similar ordinal regression model with sex,  
208 study site, index BFCRS score, and NDD diagnosis (yes/no) as independent variables, the  
209 presence of a NDD diagnosis was associated with a lower odds of clinical improvement (OR  
210 0.59; 95% CI: 0.36 to 0.95;  $p = 0.032$ ), while no other variables were significantly associated  
211 with response to treatment (Table S1).

## 212 **Discussion**

213 In this multi-site sample of 165 pediatric patients with catatonia treated within two large  
214 health systems, patients demonstrated substantial improvement in catatonia during  
215 hospitalization as measured by CGI-I scores and discharge BFCRS scores. Patients were most  
216 commonly treated with benzodiazepines, and a smaller portion were treated with ECT.  
217 Strikingly, treatment course and outcomes for neurotypical versus NDD children were different.  
218 Children with NDDs were more likely to receive more benzodiazepines and were less likely to  
219 recover fully from their illness. Additionally, children with NDDs had shorter lengths of stay,  
220 suggesting that children with NDDs may not be fully treated or may be discharged at an earlier  
221 stage in treatment.

222 Nearly all patients in this cohort were treated with a benzodiazepine, of which lorazepam  
223 was the most frequently utilized. The median patient had a maximum daily dosing of lorazepam  
224 of 6 mg, although there was substantial variation in this dosing. Benzodiazepines, particularly  
225 lorazepam, have demonstrated efficacy for the treatment of catatonia for more than 40 years,<sup>26,27</sup>  
226 but despite this long history, there remain significant questions about optimal dosing and the  
227 overall efficacy of lorazepam for autistic patients with catatonia.<sup>7,16,28</sup> A small randomized

228 controlled crossover trial of lorazepam, dosed at 6 mg of lorazepam daily, in adult psychiatric  
229 inpatients with chronic catatonic schizophrenia failed to demonstrate a benefit from this  
230 treatment.<sup>29</sup> The difference in efficacy in that trial compared to that observed here could be  
231 related to differences in weight-adjusted dosing in pediatrics, different treatment responsiveness  
232 of chronic vs. acute catatonia, diagnostic differences, or non-specific effects of general hospital  
233 treatment in patients in this sample. Systematic studies are needed to determine optimal  
234 treatment of pediatric catatonia.

235         Of the patients who were treated with a benzodiazepine, 21.5% of them required  
236 treatment with more than one benzodiazepine, most often longer acting agents such as  
237 clonazepam and diazepam, and of these patients, the majority of them had a diagnosis of autism  
238 spectrum disorder. Future randomized clinical trials of benzodiazepine treatment of pediatric  
239 catatonia will be required to determine optimal pharmacologic agents, dosing, and efficacy of  
240 treatment relative to placebo. By the time of discharge, most patients remained on a  
241 benzodiazepine, although at lower doses (median of 3 mg lorazepam equivalents per day); to our  
242 knowledge, there is no prospective data to support how to taper benzodiazepines in this  
243 population following discharge.

244         In this cohort, 14.5% of pediatric catatonia patients required treatment with ECT. This  
245 procedure has established efficacy in neurodiverse and neurotypical patients with catatonia,  
246 including those refractory to medication treatment,<sup>6,30,31</sup> but remains legally restricted in many  
247 US states<sup>32</sup> and with sociodemographic disparities in access.<sup>33,34</sup> Barriers to access to ECT in  
248 youth have been associated with substantial harm,<sup>35,36</sup> and results from this cohort point strongly  
249 to the critical need for ECT access in young patients with catatonia.

250 Baseline catatonia severity as measured using the BFCRS was not, however, correlated  
251 with hospital LOS nor was it associated with the odds of favorable response to treatment in an  
252 adjusted ordinal regression on CGI-I scores. The psychometric properties of the BFCRS have  
253 been explored in numerous prior studies,<sup>37-39</sup> its relationship with clinical outcomes has not been  
254 investigated. These results suggest that, while the BFCRS may be an appropriate tool for  
255 identifying patients with catatonia, a higher BFCRS score may not be predictive of meaningful  
256 clinical outcomes.

257 Baseline rates of NDDs were high in this sample at 50.3%, and despite a higher rate of  
258 transitioning between specific benzodiazepines in the autism cohort, patients with and without  
259 NDDs did not differ substantially in benzodiazepine dosing or rate of ECT requirement. Despite  
260 these similar treatments, patients with NDDs had a lower response to treatment in a model  
261 adjusting for other baseline patient characteristics. Catatonia can be challenging to diagnose in  
262 patients with NDDs due to overlap between baseline features of such disorders and catatonic  
263 signs such as social-emotional impairment, repetitive behaviors, or impulsivity.<sup>16,18</sup> Moreover,  
264 previous reports of autistic individuals with significant catatonia symptoms have demonstrated  
265 refractoriness to benzodiazepines.<sup>7,28</sup> The results of our study suggest that the timely  
266 identification of catatonia in NDD patients is critical, as they may derive substantial benefit from  
267 treatment. Patients with NDDs had overall shorter length of medical hospitalization, however,  
268 and were less likely to be psychiatrically hospitalized than neurotypical youth with catatonia.  
269 While this could be interpreted as a positive prognostic sign that individuals with NDDs require  
270 less intensive treatment, the reality is more likely that limitations in bed availability for inpatient  
271 treatment for individuals with NDD meant access was limited, and not that such patients would  
272 not benefit from additional treatment.<sup>40</sup>

273 Strengths of this study include a large sample size relative to prior publications in  
274 pediatric catatonia. Moreover, the incorporation of two geographically-distinct study sites  
275 enhances generalizability. Inclusion criteria were broad, incorporating a range of medical,  
276 psychiatric, and neurodevelopmental comorbidities. Limitations derive from the use of real-  
277 world clinical records generated as part of routine clinical care. As patients could only be  
278 included in the cohort if diagnosed with catatonia, the rate of under-diagnosis or the potential  
279 treatment responsiveness of unidentified cases of catatonia cannot be determined. Moreover, as  
280 treatments were provided as per routine care and not from a predesigned protocol, it remains  
281 unclear if patients would have benefitted from alternative treatment strategies, and so this study  
282 can only describe the treatments that were given. Additionally, the BFCRS used for catatonia  
283 assessment in this study has not been specifically validated for use in pediatric or neurodiverse  
284 patients, which should be considered when comparing data across studies. Furthermore, results  
285 from these academic health systems may not translate to other healthcare settings or to  
286 populations of different sociodemographic groups.

## 287 **Conclusion**

288 In a multi-site retrospective cohort of 165 pediatric catatonia patients receiving inpatient  
289 treatment, there was a substantial reduction in catatonic symptom severity with treatment. Nearly  
290 all patients were treated with benzodiazepines, with ECT utilized in 14.5% of pediatric catatonia  
291 patients. Index BFCRS score did not correlate with hospital length of stay or odds of clinical  
292 improvement. Patients with NDDs had shorter hospital LOS but lower odds of clinical response  
293 in an ordinal regression model. Further research under controlled conditions is needed to  
294 optimize and ensure equitable catatonia treatment in both neurotypical and NDD youth.

## 295 Bibliography


- 296 1. Rogers JP, Oldham MA, Fricchione G, et al. Evidence-based consensus guidelines for the  
297 management of catatonia: Recommendations from the British Association for  
298 Psychopharmacology. *J Psychopharmacol*. 2023;37(4):327-369.  
299 doi:10.1177/02698811231158232
- 300 2. Heckers S, Walther S. Catatonia. *N Engl J Med*. 2023;389(19):1797-1802.  
301 doi:10.1056/NEJMra2116304
- 302 3. Luccarelli J, Kalinich M, Fernandez-Robles C, Fricchione G, Beach SR. The Incidence of  
303 Catatonia Diagnosis Among Pediatric Patients Discharged From General Hospitals in the  
304 United States: A Kids' Inpatient Database Study. *Front Psychiatry*. 2022;13:878173.  
305 doi:10.3389/fpsyt.2022.878173
- 306 4. Smith JR, York T, Baldwin I, Fuchs C, Fricchione G, Luccarelli J. Diagnostic features of  
307 paediatric catatonia: multisite retrospective cohort study. *BJPsych Open*. 2024;10(3):e96.  
308 doi:10.1192/bjo.2024.61
- 309 5. Cornic F, Consoli A, Tanguy ML, et al. Association of adolescent catatonia with increased  
310 mortality and morbidity: evidence from a prospective follow-up study. *Schizophr Res*.  
311 2009;113(2-3):233-240. doi:10.1016/j.schres.2009.04.021
- 312 6. Smith JR, Baldwin I, Termini KA, McGonigle T, Vandekar S, Luccarelli J. Use of ECT for  
313 Children With and Without Catatonia: A Single-Site Retrospective Analysis. *J ECT*.  
314 Published online January 25, 2024. doi:10.1097/YCT.0000000000000993
- 315 7. Smith JR, Baldwin I, York T, et al. Alternative psychopharmacologic treatments for pediatric  
316 catatonia: a retrospective analysis. *Front Child Adolesc Psychiatry*. 2023;2:1208926.  
317 doi:10.3389/frcha.2023.1208926
- 318 8. Benarous X, Consoli A, Raffin M, et al. Validation of the Pediatric Catatonia Rating Scale  
319 (PCRS). *Schizophrenia Research*. 2016;176(2-3):378-386. doi:10.1016/j.schres.2016.06.020
- 320 9. Benarous X, Raffin M, Ferrafiat V, Consoli A, Cohen D. Catatonia in children and  
321 adolescents: New perspectives. *Schizophrenia Research*. 2018;200:56-67.  
322 doi:10.1016/j.schres.2017.07.028
- 323 10. Becker JE, Smith JR, Hazen EP. Pediatric Consultation-Liaison Psychiatry: An Update and  
324 Review. *Psychosomatics*. 2020;61(5):467-480. doi:10.1016/j.psym.2020.04.015
- 325 11. Raffin M, Consoli A, Giannitelli M, et al. Catatonia in Children and Adolescents: A High  
326 Rate of Genetic Conditions. *Journal of the American Academy of Child & Adolescent*  
327 *Psychiatry*. 2018;57(7):518-525.e1. doi:10.1016/j.jaac.2018.03.020

- 328 12. Smith JR, Baldwin I, Lim S, Luccarelli J. Symptoms of Catatonia Observed in Down  
329 Syndrome Regressive Disorder: A Retrospective Analysis. *J Autism Dev Disord*. Published  
330 online February 22, 2024. doi:10.1007/s10803-024-06249-x
- 331 13. Termini K, Anand E, Hickox T, Richter LD, Smith JR. Manifestation of Catatonia in an  
332 Adolescent With 22q11.2 Syndrome. *Journal of the American Academy of Child &*  
333 *Adolescent Psychiatry*. Published online June 2023:S0890856723003453.  
334 doi:10.1016/j.jaac.2023.05.028
- 335 14. Hauptman AJ, Cohen D, Dhossche D, Raffin M, Wachtel L, Ferrafiat V. Catatonia in  
336 neurodevelopmental disorders: assessing catatonic deterioration from baseline. *The Lancet*  
337 *Psychiatry*. 2023;10(3):228-234. doi:10.1016/S2215-0366(22)00436-9
- 338 15. Hauptman AJ, Cohen D, Dhossche D, Raffin M, Wachtel L, Ferrafiat V. Catatonia in  
339 neurodevelopmental disorders: assessing catatonic deterioration from baseline. *The Lancet*  
340 *Psychiatry*. 2023;10(3):228-234. doi:10.1016/S2215-0366(22)00436-9
- 341 16. Vaquerizo-Serrano J, Salazar De Pablo G, Singh J, Santosh P. Catatonia in autism spectrum  
342 disorders: A systematic review and meta-analysis. *Eur Psychiatry*. 2022;65(1):e4.  
343 doi:10.1192/j.eurpsy.2021.2259
- 344 17. Carroll BT, Kirkhart R, Ahuja N, et al. Katatonia. *Psychiatry (Edgmont)*. 2008;5(12):42-50.
- 345 18. Smith JR, York T, Warn S, Borodge D, Pierce DL, Fuchs DC. Another Option for  
346 Aggression and Self-Injury, Alternative Benzodiazepines for Catatonia in Profound Autism.  
347 *J Child Adolesc Psychopharmacol*. 2023;33(3):109-117. doi:10.1089/cap.2022.0067
- 348 19. Zappia KJ, Shillington A, Fosdick C, Erickson CA, Lamy M, Dominick KC.  
349 Neurodevelopmental Disorders Including Autism Spectrum Disorder and Intellectual  
350 Disability as a Risk Factor for Delayed Diagnosis of Catatonia. *J Dev Behav Pediatr*.  
351 Published online March 7, 2024. doi:10.1097/DBP.0000000000001252
- 352 20. Bush G, Fink M, Petrides G, Dowling F, Francis A. Catatonia. I. Rating scale and  
353 standardized examination. *Acta Psychiatrica Scandinavica*. 1996;93(2):129-136.  
354 doi:<https://doi.org/10.1111/j.1600-0447.1996.tb09814.x>
- 355 21. Danciu I, Cowan JD, Basford M, et al. Secondary Use of Clinical Data: the Vanderbilt  
356 Approach. *J Biomed Inform*. 2014;52:28-35. doi:10.1016/j.jbi.2014.02.003
- 357 22. Busner J, Targum SD. The Clinical Global Impressions Scale. *Psychiatry (Edgmont)*.  
358 2007;4(7):28-37.
- 359 23. Gwet KL. Computing inter-rater reliability and its variance in the presence of high  
360 agreement. *British Journal of Mathematical and Statistical Psychology*. 2008;61(1):29-48.  
361 doi:10.1348/000711006X126600
- 362 24. White H. A Heteroskedasticity-Consistent Covariance Matrix Estimator and a Direct Test for  
363 Heteroskedasticity. *Econometrica*. 1980;48(4):817-838. doi:10.2307/1912934

- 364 25. Jr FEH. rms: Regression Modeling Strategies. Published online March 11, 2024. Accessed  
365 May 22, 2024. <https://cran.r-project.org/web/packages/rms/>
- 366 26. Fricchione GL, Cassem NH, Hooberman D, Hobson D. Intravenous Lorazepam in  
367 Neuroleptic-Induced Catatonia. *Journal of Clinical Psychopharmacology*. 1983;3(6):338-  
368 342.
- 369 27. Hirjak D, Fricchione G, Wolf RC, Northoff G. Lorazepam in catatonia - Past, present and  
370 future of a clinical success story. *Schizophr Res*. Published online February 17, 2023:S0920-  
371 9964(23)00057-9. doi:10.1016/j.schres.2023.02.015
- 372 28. Wachtel LE. Treatment of catatonia in autism spectrum disorders. *Acta Psychiatrica*  
373 *Scandinavica*. 2019;139(1):46-55. doi:10.1111/acps.12980
- 374 29. Ungvari GS, Chiu HFK, Chow LY, Lau BST, Tang WK. Lorazepam for chronic catatonia: a  
375 randomized, double-blind, placebo-controlled cross-over study. *Psychopharmacology*.  
376 1999;142(4):393-398. doi:10.1007/s002130050904
- 377 30. Luccarelli J, Fernandez-Robles C, Wininger B, Becker JE, Hazen EP, Henry ME. Rapid  
378 Resolution of Prolonged Benzodiazepine-Refractory Catatonia with ECT in an Adolescent  
379 Patient: a Case Report. *J ECT*. 2022;38(3):219-220. doi:10.1097/YCT.0000000000000841
- 380 31. Smith JR, Hopkins CE, Xiong J, Luccarelli J, Shultz E, Vandekar S. Use of ECT in Autism  
381 Spectrum Disorder and/or Intellectual Disability: A Single Site Retrospective Analysis. *J*  
382 *Autism Dev Disord*. Published online December 17, 2022. doi:10.1007/s10803-022-05868-6
- 383 32. Livingston R, Wu C, Mu K, Coffey MJ. Regulation of Electroconvulsive Therapy: A  
384 Systematic Review of US State Laws. *J ECT*. 2018;34(1):60.  
385 doi:10.1097/YCT.0000000000000460
- 386 33. Luccarelli J, Henry ME, McCoy TH. Demographics of Patients Receiving Electroconvulsive  
387 Therapy Based on State-Mandated Reporting Data. *J ECT*. 2020;36(4):229-233.  
388 doi:10.1097/YCT.0000000000000692
- 389 34. Luccarelli J, McCoy TH, Henry ME, Smith F, Beach SR, Fernandez-Robles C. The use of  
390 electroconvulsive therapy for children and adolescents in general hospitals: A 2019 kids'  
391 inpatient database analysis. *Gen Hosp Psychiatry*. 2023;82:95-100.  
392 doi:10.1016/j.genhosppsy.2023.03.012
- 393 35. Couse M, Makhinson M, Kelly P. Regulatory and Service System Challenges in Accessing  
394 Electroconvulsive Therapy for Catatonia in the Presence of Autism Spectrum Disorder. *J Am*  
395 *Acad Child Adolesc Psychiatry*. 2024;63(3):293-295. doi:10.1016/j.jaac.2023.09.540
- 396 36. Ong M, Patterson E, Stewart L, Pierce D, Smith JR. Morbidity Due to Disparity in Pediatric  
397 Electroconvulsive Therapy. *J Am Acad Child Adolesc Psychiatry*. 2023;62(3):279-281.  
398 doi:10.1016/j.jaac.2022.07.850




- 399 37. Cuevas-Esteban J, Serrat F, Baladon L, Rabaneda-Lombarte N, Díez-Quevedo C, Iglesias-  
400 González M. Factor analysis and validation of the Bush Francis catatonia rating scale-Spain  
401 version. *The European Journal of Psychiatry*. 2023;37(4):100221.  
402 doi:10.1016/j.ejpsy.2023.07.004
- 403 38. Wilson JE, Niu K, Nicolson SE, Levine SZ, Heckers S. The diagnostic criteria and structure  
404 of catatonia. *Schizophrenia Research*. 2015;164(1-3):256-262.  
405 doi:10.1016/j.schres.2014.12.036
- 406 39. Sienaert P, Rooseleer J, De Fruyt J. Measuring catatonia: A systematic review of rating  
407 scales. *Journal of Affective Disorders*. 2011;135(1):1-9. doi:10.1016/j.jad.2011.02.012
- 408 40. Melvin CL, Barnoux M, Alexander R, et al. A systematic review of in-patient psychiatric  
409 care for people with intellectual disabilities and/or autism: effectiveness, patient safety and  
410 experience. *BJPsych Open*. 2022;8(6):e187. doi:10.1192/bjo.2022.571
- 411
- 412



413

414 Figure 1: Kernel density plot of BFCRS score at admission (red) and discharge (blue) for  
415 patients with a documented discharge BFCRS (N = 103)

416



417  
418

419 Figure 2: Scatterplot of initial BFCRS score vs. length of medical hospitalization in days.  
420 Patients with an NDD are colored in blue, while those without an NDD are colored red.

421

422

423

424

	Overall		NDD History		No NDD History		Significance
	N	%	N	%	N	%	
<i>N</i>	165		83		82		
<i>Sex</i>							$X^2 (1, N = 165) = 4.44, p = 0.035$
<i>Male</i>	92	55.8	53	63.9	39	47.6	
<i>Female</i>	73	44.2	30	36.1	43	52.4	
<i>Age (median, IQR)</i>	15 (12 to 16)		14 (11 to 16)		15 (14 to 17)		$U = 2504, p = 0.003$
< 13	42	25.5	28	33.7	14	17.1	
13-15	54	32.7	26	31.2	28	34.1	
16-18	69	41.8	29	34.9	40	48.8	
<i>Study Site</i>							$X^2 (1, N = 165) = 2.15, p = 0.142$
<i>Site 1</i>	136	82.4	72	86.7	64	78.0	
<i>Site 2</i>	29	17.6	11	13.3	18	22.0	
<i>Race</i>							$X^2 (3, N = 165) = 5.91, p = 0.116$
<i>Asian</i>	6	3.6	3	3.6	3	3.7	
<i>Black</i>	43	26.1	16	19.3	27	32.9	
<i>White</i>	107	64.8	61	73.5	46	56.1	
<i>Other</i>	9	5.5	3	3.6	6	7.3	
<i>Ethnicity</i>							$X^2 (1, N = 165) = 5.86, p = 0.015$
<i>Hispanic</i>	25	15.2	7	8.4	18	22.0	
<i>Not Hispanic</i>	140	84.8	76	91.6	64	78.0	
<i>Primary Diagnosis</i>							$X^2 (4, N = 165) = 53.5, p < 0.001$
<i>Unspecified Catatonia</i>	40	24.2	26	31.3	14	17.1	
<i>Mood or Trauma Disorder</i>	23	13.9	7	8.4	16	19.5	
<i>Psychotic Disorder</i>	46	27.9	12	14.5	34	41.5	
<i>Medical Condition</i>	25	15.2	7	8.4	18	22.0	
<i>Neurodevelopmental Disorder</i>	31	18.8	31	37.3	0	0.0	
<i>Index BFCRS (median, IQR)</i>	15 (11 to 20)		17 (11 to 21)		14 (11 to 18)		$U = 2744, p = 0.031$

425


426 Table 1: baseline demographics for pediatric patients with catatonia, overall and divided by NDD  
 427 status. Listed significances compare hospitalizations for patients with NDD and those without.

	<i>Overall</i>	<i>NDD History</i>	<i>No NDD History</i>	<i>Significance (NDD vs. No NDD)</i>
Highest 24h Benzodiazepine Dose (mg lorazepam equiv; median, IQR)	6 (3 to 12)	6 (3 to 9.25)	6 (3 to 12)	U = 3202, <i>p</i> = 0.691
Discharge 24h Benzodiazepine Dose (mg lorazepam equiv; median, IQR)	3 (1.5 to 6)	3 (1.5 to 6)	3 (1.5 to 6.5)	U = 3197, <i>p</i> = 0.587
LOS for Medical Hospitalization (days; median, IQR)	5 (3 to 13)	5 (3 to 9.25)	8 (4 to 16)	U = 2604, <i>p</i> = 0.017
Total LOS (days; median, IQR)	10 (5 to 26)	6 (4 to 20)	16 (6.75 to 35.75)	U = 1927, <i>p</i> < 0.001
Received ECT (yes; N (%))	24 (14.5%)	10 (12.0%)	14 (17.1%)	$X^2(1, N = 165) = 0.838, p = 0.360$
Psychiatrically Hospitalized (yes; N (%))	63 (38.2%)	21 (25.3%)	42 (51.2%)	$X^2(1, N = 165) = 11.7, p < 0.001$
Discharged Home (yes; N (%))	150 (90.9%)	75 (90.4%)	75 (91.5%)	$X^2(1, N = 165) = 0.061, p = 0.806$
Discharge BFCRS (median, IQR)	4 (1 to 7)	5 (3 to 9)	1.5 (0 to 5)	U = 706, <i>p</i> < 0.001


428

429 Table 2: benzodiazepine dosing, hospital length of stay, ECT receipt, and discharge disease  
 430 severity for pediatric catatonia hospitalizations, both overall and divided by NDD status. Listed  
 431 significances compare hospitalizations for patients with NDD and those without.

432




433  
434 Figure S1: violin plots of the maximum benzodiazepine dose (left) and the discharge  
435 benzodiazepine dose (right) for pediatric patients with catatonia; the inset box in each plot  
436 displays median doses and IQR. Doses are listed in milligrams of lorazepam equivalents in a 24-  
437 hour period.  
438



439  
440  
441  
442  
443  
444

Figure S2: plot of admission and discharge BFCRS scores for individuals (N=103) with a documented BFCRS at time of discharge, divided by patients with NDDs (blue) and without (green). The black lines indicate the mean.



445  
446  
447 Figure S3: Scatterplot of initial BFCRS score vs. total length of stay (medical + psychiatric  
448 hospitalization) in days. Patients with an NDD are colored in blue, while those without an NDD  
449 are colored red.

450

451



<b>Variable</b>	<b>OR</b>	<b>Lower 0.95</b>	<b>Upper 0.95</b>
Age	1.11	0.87	1.40
Index BFCRS	1.03	0.71	1.48
Sex (Female)	1.39	0.88	2.20
Site (2)	0.73	0.36	1.51
NDD (yes)	0.59	0.36	0.95

452

453 Table S1: ordinal regression fit to CGI-I data adjusting for reviewer with subject-robust standard  
454 errors, with age, sex, study site, index BFCRS score, and NDD diagnosis (yes/no) as independent  
455 variables.